Trial Profile
A Phase 2 Study of CPI-0610, a Small Molecule Inhibitor of Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Malignant Peripheral Nerve Sheath Tumors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs Pelabresib (Primary)
- Indications Nerve sheath neoplasms
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2018 Planned End Date changed from 1 Mar 2020 to 17 May 2018.
- 07 Sep 2018 Planned primary completion date changed from 1 Mar 2019 to 17 May 2018.
- 07 Sep 2018 Status changed from recruiting to withdrawn prior to enrolment.